SPARK Biopharma, Inc., a company focused on the critical task of improving human health, has successfully closed a $21.0M Series A funding round. The firm specializes in providing small-molecule therapeutics, employing a distinctive phenotypic discovery approach to identify and develop new treatments.
This fresh capital infusion marks a significant milestone for SPARK Biopharma, enabling it to further its specialized work and continue its mission to bring innovative therapeutic solutions to the market, ultimately benefiting patients.















